Q&A – Clinical trials

2cureX is happy to receive a number of questions and comments from our present and from potential future shareholders.

With the present Questions & Answers (Q&A) section, we would like to make these questions and their answers publicly available. Additional questions/comments should be mailed to info@2cureX.com.

In your press release regarding recruitment of the last patient int the TICC1 trial, it is mentioned that clinical data will be available after eight weeks. When shall we expect such data to be published?

Posted on 2020-10-04
It is expected that the final clinical data of the TICC1 trial will be published in Q1 2021. It is correct as the Principal Investigator Lars Henrik Jensen stated in the press release that the patients will go through a follow-up examination eight weeks after the IndiTreat-guided treatment is started. At the follow-up the effect of the treatment is evaluated by CT scanning. Thereafter data from all patients will need to be assembled, evaluated and published. We expect this finalized in the first quarter of 2021.

Have you started enrolling patients into your clinical study?

Posted on 2018-03-20
Yes, the first patients were enrolled end of October 2017. In February 2018 we had successfully enrolled the first 10 patients.

Contact us

Please contact 2cureX for more information

Email: info@2cureX.com
Phone: +45 22115399
Web: www.IndiTreat.com

Upcoming events

December 7, 2021

CEO Fernando Andreu will present at ”Sedermeradagen Köbenhamn 2021” (Copenhagen, Denmark)

Read more

December 9, 2021

2cureX presents at HC Andersen Capital’s Virtual Growth Days (Copenhagen, Denmark)

Read more

January 20, 2022

2cureX present at Redeye Theme – Fight Cancer Seminar – Outlook 2022 (Stockholm, Sweden)

Read more

February 24, 2022

Year-End Report 2021

View previous reports

Key benefits of IndiTreat

  • Tumor resistance
    Predict tumor resistance and sensitivity to cancer drugs
  • Right cancer treatment
    Select the most appropriate treatment, in accordance with guidelines or off-label
  • Better patient outcome
    Improve patient quality of life through in vitro testing of drug efficacy on the individual patient
  • Help chemo-naïve CRC patients
    Identify the most effective treatment in chemo-naïve colorectal cancer patients
  • Help late-stage CRC patients
    Identify the most effective treatment in late-stage colorectal cancer patients
  • Functional precision medicine
    Complement the genomic characterisation of tumours with functional data on resistance and sensitivity to drugs